The Weekly Pulse — Edition 19, February 1, 2026
Published · Researched 2026-09-22
Good Signal's weekly digest: the best verified news of the week of January 26, 2026.
The week in one paragraph
The most striking cancer result in recent memory came from Memorial Sloan Kettering: in a Phase 2 trial, the immunotherapy dostarlimab (Jemperli) produced a 100 percent clinical complete response rate in 42 patients with mismatch repair–deficient locally advanced rectal cancer who completed treatment — no evidence of tumor on MRI, endoscopy, or exam, with no surgery, radiation, or chemotherapy needed. The first 24 patients evaluated held their response at a median follow-up of 26.3 months (ASCO 2024), and a later AACR 2025 update extended the rectal cohort to 49 patients, all with complete clinical response at a median follow-up of 30.2 months and 96 percent two-year recurrence-free survival. Standard treatment can leave patients with a permanent colostomy and lasting quality-of-life damage; in this trial, every patient avoided all of that. Still watching: direct social-media posts about dostarlimab weren't observed in the research pass — the social layer here is oncology press, not viral patient posts.
Rising
Functional cures are stacking up. Vertex's zimislecel — a one-time infusion of lab-grown, stem-cell-derived islet cells — delivered striking Phase 1/2 results in the 12-patient FORWARD trial, presented at the American Diabetes Association's 2025 Scientific Sessions and published in the New England Journal of Medicine: all 12 patients restored insulin secretion, eliminated severe hypoglycemic events, and hit glycemic targets; insulin use fell by an average of 92 percent; 10 of 12 came off insulin altogether at one year. Vertex has moved the program into Phase 3. The dossier states the trade-off plainly rather than hiding it: chronic immunosuppression is required, with infection, kidney, and long-term risk traded against a lifetime of insulin — a trade many patients with severe hypoglycemia would take. Still watching: Phase 3 status and the 2026 regulatory-filing timeline rest on 2025 announcements with no newer primary confirmation; two participant deaths were reported as unrelated to the therapy, but causes weren't detailed.
Kids with bigger hearts than birthday lists. Alex Anning, 7, of Tinley Park, Illinois, decided to skip a traditional birthday party and instead run a community food distribution at Carrie Bond Elementary School in Englewood, Chicago, as his 8th birthday approached in 2026. With his mother Kymbria Young, he handed out grocery bags — milk, bread, canned goods, desserts — to anyone in need, no questions asked, as a line of people stretched outside the school's doors and many families faced uncertainty from a lapse in SNAP benefits. A SNAP recipient told ABC7 Chicago she was grateful that a 7-year-old was providing for hungry people; his mother said her heart was full of joy. The pair run a nonprofit, Season to Soar, serving underserved Chicago-area communities. Still watching: the exact date of the giveaway and the number of bags served weren't captured.
Communities building at speed. Volunteers built a new playground for the North Omaha Boys & Girls Club in three days, finishing September 12, 2026 (reported by WOWT the next day). Still watching: the volunteer count and funding sources weren't captured.
Falling
"Rectal cancer always ends in a colostomy." Every patient in the dostarlimab cohort avoided surgery entirely — a treatment paradigm that may finally crack one of oncology's harshest trade-offs.
The insulin-for-life certainty. For people with type 1 diabetes and dangerous hypoglycemia unawareness, a century of finger sticks and crash fear just met its strongest clinical challenge yet.
Quiet signals
Benji's third chance. A dog adopted and returned twice was finally matched with Air Force veteran Thomas through Pets for Patriots — the first adoption via the program's new partnership with Wilson County Animal Services, finalized after Thomas's approval in early January 2026. Small, complete, worth noting rather than watching — one hard-to-place dog, one right human.
Zimislecel's Phase 3 watch. The 2026 regulatory filing timeline is still based on 2025 announcements. Watch for a primary confirmation this year — and for how the immunosuppression trade-off gets weighed publicly as the trial pool widens.
Dostarlimab beyond the clinic. The oncology press covered the 100 percent response loudly; the patient-social layer is quiet so far. Watch whether survivor communities pick up a result this striking.
Scoreboard
N/A — editions written out of sequence; no prior calls to grade.
One line to close
Tumors vanishing, insulin retired, and a 7-year-old choosing a food line over a birthday cake — medicine moved mountains this week, and a child fed a neighborhood.